Sunesis

$1.43
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.05 (+3.68%) Today
+$0.02 (+1.42%) As of 11:00 PM UTC after-hours

Why Robinhood?

You can buy or sell Sunesis and other stocks, options, and ETFs commission-free!

About SNSS

Sunesis Pharmaceuticals, Inc. engages in the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. The firm's activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The company was founded on February 10, 1998 and is headquartered in South San Francisco, CA. The listed name for SNSS is Sunesis Pharmaceuticals, Inc. Common Stock.

CEO
Dayton Misfeldt
Employees
24
Headquarters
South San Francisco, California
Founded
1998
Market Cap
25.51M
Price-Earnings Ratio
Dividend Yield
Average Volume
546.74K
High Today
$1.45
Low Today
$1.33
Open Price
$1.39
Volume
1.10M
52 Week High
$11.30
52 Week Low
$1.12

Collections

SNSS Earnings

-$0.17
-$0.11
-$0.06
$0.00
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Estimated
per share
Actual
Available Nov 16, After Hours

You May Also Like